

IWGDF Guidelines – Disclosure of interest form



Name: Dr Fran Game

Affiliation: University Hospitals of Derby and Burton NHS Foundation Trust, Derby UK

Position: Clinical Director R&D

IWGDF Working Group: Editorial Board, Wound Healing, Charcot

For the following items, please disclose any interest from the past five years that might be perceived by others as potentially influencing your judgment in any topic in the IWGDF Guideline(s) that you contribute to.

- Ancillary positions:

Scientific Secretary, Executive Committee of the Diabetic Foot Study Group Europe

Regional Clinical Director, Diabetes, NHS England, Midlands UK

Chair IWGDF editorial Board

Chair National Diabetes Footcare audit England and Wales.

- Personal financial interests:

None

- Personal relations (this includes personal relations or relations via close family that might be perceived by others as potentially influencing your judgment):

None

- Externally funded research (this includes research funding awarded to you as project member, or to your department, for funding that might be perceived by others as potentially influencing your judgment). If yes, name the title/topic of the grant.

NIHR (HTA) £1,769,583 2017-2021 Multiple Interventions for Diabetic Foot Ulcer Treatment (MIDFUT) Trial (Co-Applicant)

Medilink East Midlands (MTT-ISG) £100, 025. 2017-2019. Effectiveness of Omnigen for treating Diabetic Foot Ulcers –a pilot study. (Chief Investigator)

NIHR (HTA) £1,772,000 2018-2023. CODIFI2: Randomised controlled trial of swab versus tissue sampling for infected diabetic foot ulcers, and comparison of culture versus molecular processing techniques. (Clinical Chief Investigator)

MRC £902,523 2018 - MICA: Monitoring wound healing using multi-parameter optical fibre sensors (Co-applicant)

NIHR PGfAR £2,531,202 2019- Reducing the impact of diabetic foot ulcers on patients and the health service: the REDUCE programme (Chief Investigator).

NIHR (PGfAR) £2,187,052 2021-2025 Developing and Evaluating A Multifactorial Intervention to Improve Cardiovascular Outcomes in Adults with Type 2 Diabetes and Current or Previous Diabetic Foot Ulcers (MiFoot) (Co-applicant)

- Other disclosures:

None

When you have nothing to disclose, please state here:

Signature and date: